Introduction
Cytogenetic and molecular genetic approaches have revealed that non-random genomic alterations in chromosome 1p are associated with a number of human malignancies, and therefore have suggested the existence of cancer related genes on chromosome 1p (Caron, 1995; Schwab et al., 1996) . Loss of heterozygosity (LOH) for chromosome 1p is frequently observed in a variety of tumors. These include neuroblastomas (Ariyama et al., 1995; Cheng et al., 1995; White et al., 1997) , meningiomas (Ishino et al., 1998) , pheochromocytomas, medullary thyroid carcinomas and neuroendocrine carcinoma (Moley et al., 1992) , T cell acute lymphoblastic leukemia (Iolascon et al., 1997) , colorectal carcinoma (Bomme et al., 1998; Di Vinci et al., 1998; Praml et al., 1995) , mesothelioma (Lee et al., 1996) , hepatoma (Chen et al., 1996) , endometrial carcinoma (Arlt et al., 1996) and breast carcinomas (Borg et al., 1992; Munn et al., 1995; Nagai et al., 1995; Tsukamoto et al., 1998) . A unique category of germ cell tumors, childhood endodermal sinus tumors involving the testis and extragonadal region in children less than 4 years of age, show recurrent cytogenetic abnormalities including deletion of distal 1p region (Perlman et al., 1996) . Such cytogenetic and mapping data have envisaged the presence of one or more important tumor suppressor genes on chromosome 1p. A close homolog of tumor suppressor protein p53, p73, frequently deleted in neuroblastomas, melanomas and breast cancers, has also been assigned to human chromosome 1p36 (Caput, 1997; Jost et al., 1997; Kaghad et al., 1997; Mai et al., 1998) .
We here describe the cloning and characterization of a gene that assigns to chromosome 1p31. We have cloned two dierentially spliced forms of the cDNA encoding 84-kDa full-length (736 amino acids, a.a.) and 41-kDa C-terminus truncated (363 a.a.) proteins. Expression analyses revealed that the 4.4 kb transcript and the 84-kDa protein are down-regulated in some transformed cell lines and in others the 2.7 kb transcript and the 41-kDa protein are enriched. Exogenous expression of the full-length, but not the C-terminus truncated form of the protein, resulted in reduced colony forming eciency of NIH3T3 cells suggesting the growth suppressive activity of the 84-kDa form. The gene is therefore named Gros1 for Growth Suppressor on chromosome 1. An independent study cloned rat homolog of Gros1 as a novel leucine proline-enriched basement membrane-associated proteoglycan, leprecan (Wassenhove-McCarthy and McCarthy, 1999) . Taken together, Gros1/leprecan is a novel proteoglycan and tumor suppressor whose genetic alterations may be involved in chromosome 1 linked human malignancies.
Results and discussion
Cloning and characterization of Gros1 cDNA By a comparison of proteins from plasma membrane Triton X-100 insoluble fractions from normal (CMEF) and immortal (NIH3T3 and RS-4) murine cells, we noted a protein of nearly 33-kDa (called p33) that was absent in CMEF (Wadhwa et al., 1991) . Lysates of NIH3T3 cells were used to isolate the protein from SDSpolyacrylamide gels that was used for raising a polyclonal antibody. The anti-p33 antibody thus obtained was used for immunocloning as described previously (Wadhwa et al., 1993) . Immunoscreening of RS-4 cDNA library led to the isolation of ®ve cDNA clones that were characterized by partial sequencing. Three clones showed identities to known genes, viz., FusCHOP, G-utrophin and dystrophin, while the other two clones had no matches in the DNA sequence databases. The in vitro translated products of these two novel clones could not be precipitated with the anti-p33 antibody indicating that these may not be related to p33.
The complete sequence of the clone #7 (1.0 kb) contained one predicted open reading frame (ORF) encoding a putative protein of approximately 31-kDa. It had no signi®cant homology to any of the sequences in the DNA and protein data banks. The in vitro translation of the clone yielded a protein of the predicted size (data not shown) con®rming the existence of an ORF. The #7 cDNA (1.0 kb fragment) was used as a probe for Northern analysis. It reacted to two transcripts, 4.4 and 2.7 kb, in human tissues. These were weakly expressed in many tissues while the short form was signi®cantly high expressed in placenta, testis and ovary ( Figure 1a ). The membrane was also probed with actin for loading control (not shown). Human cancer cell lines such as promyelocytic leukemia (HL-60), cervical carcinoma (HeLa), chronic myelogenous leukemia (K-562), colon adenocarcinoma (SW480) and melanoma (G361) showed predominant expression of the 2.7 kb transcript with negligible expression of the 4.4 kb transcript. In contrast, the normal human ®broblasts (HFF5, BF-10 and MRC-5) showed predominant expression of the 4.4 kb transcript. The expression of the 2.7 kb transcript was 8-and 25-fold less than that of the 4.4 kb form in case of HFF-5 and BF-10, respectively, and was not detected in MRC-5 cells (Figure 1b) . Thus, an upregulation of expression of the 2.7 kb form and a loss/down regulation of expression of the 4.4 kb transcript appeared to be associated with the transformed phenotype of many human cell types.
Mouse cells showed two Gros1 related transcripts of approximately 3.3 and 2.7 kb (Figure 2a ). The two transcripts were detected in all tissues although very weakly expressed in brain and spleen. Testis showed only a negligible level of expression of the 3.3 kb transcript. RT ± PCR revealed a higher level of expression in mouse ovary ( Figure 2b) ; it was similar to the expression seen in the human ovary. Taken together with the above data (loss/down regulation of 4.4 kb and upregulation of the 2.7 kb Gros1 transcript in many human transformed cells), it alluded that the larger transcript may encode a protein having growth suppressive function and the protein coded by lower transcript may be growth supporting. Therefore, we performed cloning, characterization and functional assay. The gene was named Gros1 for Growth suppressive eect of the murine 85-kDa Gros1-L protein as described below.
The size of the two Gros1 transcripts was bigger than the initially isolated cDNA clone #7 (1 kb) that lacked the stop codons¯anking the ORF. Therefore, we chose to clone longer cDNAs from mouse and human testis cDNA libraries by using #7 clone as a probe. Four positive clones were obtained from a human testis cDNA library that had inserts of 2.1, 2.5, 2.6, and 2.8 kb. PCR with a set of #7 speci®c primers yielded a fragment of approximately 500 bp from three clones that had inserts of 2.1, 2.5 or 2.6 kb. The clone with an insert of 2.8 kb, however, yielded an 800 bp PCR fragment suggesting that there may be alternatively spliced forms of the gene. Complete sequences of these clones, gb accession numbers AF097432 (hGros1-L) and AF097431 (hGros1-S), supported the interpretation that they represent alternatively spliced forms. The clones #7-2.1, #7-2.5, and #7-2.6 kb were derived from the same type of human #7 transcript (AF097432) and the #7-2.8 kb clone diered from these three by having two insertions of 55 and 174 bp corresponding to the nucleotide residues 1131 ± 1185 and 1330 ± 1503 of AF097431 (Figure 3) . The 2.6 kb clone, named hGros1-L, is predicted to encode an 84-kDa protein containing 736 amino acids and has a leucine rich repeat, leucine zipper. The 2.8 kb clone has a premature termination due to the presence of the ®rst insertion and encodes a 41-kDa protein containing 363 amino acids and is named hGros1-S (Figures 3 and 4) . The shorter form of the protein lacks the leucine zipper. Screening of a mouse testis cDNA library did not yield any clones longer than the original clone #7. It, however, matched to many mouse EST clones that were overlapped, but all of these EST clones lacked the 5' end of the transcript that was initially obtained as clone #7. By aligning the clone #7 and overlapping EST clones, we derived a cDNA sequence, gb accession number AF165163 (mGros1-L) that is predicted to encode a protein of approximately 85-kDa, similar to the hGros1-L (84.8% homology at cDNA and 83.9% homology at protein level) (Figure 4 ). An EST clone (AA030295) with a deletion of 94 bp was also found. Sequence analysis of this clone, gb accession number AF165164, revealed that it can yield a predicted protein of 61-kDa named mGros1-S (Figure 4 ). By using the 5' fragment of clone #7 and a 3' fragment of an EST (Gene bank accession number, AA498928), we constructed a mammalian expression plasmid encoding a 85-kDa mGros1-L protein. Clone #7 was also inserted into a mammalian expression plasmid to code for a short protein (368 a.a.) lacking the carboxy-terminus.
Existence of more than one form of Gros1 protein in cells
The antibody raised against the N-terminal recombinant Gros1 protein was used for Western analysis of lysates from mouse, human and monkey cells. Consistent with the two transcripts and predictions of ORFs from the cloned cDNAs, the antibody reacted to proteins of approximately 84-and 43-kDa from human normal lung ®broblasts, MRC-5 (Figure 5a , lane 4). Human transformed cells such as A549, C33A, NEC8, and Saos-2 showed dierent sizes of the anti-Gros1 antibody reactive proteins (Figure 5a , lanes 5 ± 9). Lysates from mouse cells such as NIH3T3, RS-4 and Balb/c 3T3 showed the presence of approximately 85-, 61-, 42-, 36-and 34-kDa anti-Gros1 antibody reactive proteins ( Figure 5a, lanes 1 ± 3) . The 34-and 32-kDa forms migrated very closely on SDS-polyacrylamide gels and the 60-kDa form was barely detectable in some gels. Since there were only two transcripts detected by Northern analysis, it is suggestive that many bands may represent endogenously cleaved or modi®ed forms of the protein. COS 7 cells, on the other hand, showed the presence of 60-, 40-and 32-kDa anti-Gros1 antibody reactive proteins. An 84 ± 85 kDa protein was not detected in COS 7 cells. We therefore chose these cells for transfection of human Gros1-L and Gros1-S cDNAs. As expected, these led to the detection of exogenous expression of the two forms as 84-and 43-kDa proteins (Figure 5a , lanes 10 ± 12) in addition to the endogenously expressed forms. The exact identity of multiple bands detected by anti-Gros1 antibody in mouse and human cells warrants further investigation. Although the possibility that some of these bands may represent cross reactivity to the antibody is not ruled out, the fact that their size dier in dierent cell types (Figure 5a ) suggests that these are more likely to represent the dierent forms of the protein. Together with the cloning data, these results suggested the existence of more than one form of the protein.
Differential subcellular localization of hGros1-L and hGros1-S forms COS 7 cells transfected with plasmids encoding GFPtagged hGros1-L (2.6 kb cDNA) and hGros1-S (2.8 kb cDNA) showed the expression of 114-and 73-kDa proteins by Western analysis with anti-GFP antibody ( Figure 5a , lanes 13 ± 15). The cells expressing exogenous GFP-tagged 114-kDa Gros1-L protein showed cytoplasmic¯uorescence that was clearly excluded from the nucleus. However, cells transfected with GFP-tagged 73-kDa Gros1-S protein showed cytoplasmic and nuclear localization (Figure 5b ). Such dierential localizations of the two putative alternatively spliced forms of the Gros1 gene suggest that they may have dierent functions.
Biological activity of Gros1
Mammalian expression plasmids containing the mouse Gros1-L cDNA encoding an 85-kDa protein or a truncated form encoding only the N-terminal 368 amino acids or an antisense construct was transfected to NIH3T3 cells. Thirty-six G418-resistance independent clones were analysed by Northern blot hybridization for the expression of exogenous Gros1-L and its truncated form. The expression of the full-length Gros1-L sense constructs was detected as a 3.0 kb transcript that migrated in between the two endogenous murine Gros1 transcripts of 3.3 and 2.7 kb. The truncated form yielded only a 1.3 kb exogenous transcript (Figure 6a ). The expression of the antisense resulted in much fainter expression of the two endogenous transcripts ( Figure  6a ). The blot was probed with actin for a loading control (not shown) and was stained with ethidium bromide (Figure 6a ). The data showed that the variability seen in the endogenous expression of Gros1 transcript was due to loading dierences (Figure 6a , compare lanes 1 and 4). Stable clones with antisense expression, however, depicted low level of endogenous transcript in spite of the equivalent loading to the control lanes (Figure 6a , Figure 6 Biological activity of Gros1/leprecan (a) Northern analysis of NIH3T3 cells stably transfected with empty vector, clones V-702 and -733), full-length mouse Gros1 (clones S-2, -4, -6, -8 and -10), truncated mouse or antisense construct (clones AS-1, -2, -3, -10, -12 and -723). Full-length exogenous transcript migrated between the two endogenous transcripts (lanes 8 ± 12), truncated form gave 1.3 kb transcript (lanes 5 ± 7) and the antisense resulted in diminished expression of both the endogenous transcripts (lanes 13 ± 17). Ethidium bromide staining of the blot is shown as a loading control. The faint signals in lanes 1 and 2 are due to less loading. The faint signals in lanes 13 ± 17 are due to antisense expression that can also be seen as a faint band at 1.3 kb. (b) Colony forming assay of control, antisense and sense derivatives. Sense derivatives showed decreased colony-forming eciency (both colony number and size) as compared to the empty vector transfected controls. Antisense derivatives showed high colony forming eciency a Figure 5 Western blotting of mouse, human and monkey cell lysates with anti-Gros1 antibody. Mouse cells showed the presence of 85-, 61-, 42-, 36-and 34-kDa Gros1-related proteins (a, lanes 1 ± 3). Human cells showed 85-, 66-, 64-, 43, 36-and 34-kDa Gros1-related proteins that were dierentially expressed in normal and dierent transformed cells (lanes 4 ± 9). COS7 cells showed 64-, 40-and 32-kDa Gros1-related proteins. Expression of the exogenous hGros1-L and -S was detected as 84-and 41-kDa proteins shown by ®lled and empty arrow heads, respectively (lanes 10 ± 12). Expression of GFP-tagged hGros1-L and hGros1-S was detected as 114-and 73-kDa proteins with anti-GFP antibody (lanes 13 ± 15). (b) Whereas GFP related¯uorescence of GFP-tagged hGros1-L was seen exclusively in the cytoplasm (a), GFP-tagged hGros1-S was seen in the nucleus also (b) a Oncogene Gros1, a potential growth suppressor on chromosome 1 SC Kaul et al compare lanes 4 and 12 ± 16). The clones with higher level of expression of the full and truncated forms and the antisense derivatives that showed negligible expression of the endogenous Gros1 transcripts were subjected to colony forming assays ( Figure 6b and Table 1 ). The clones transfected with the truncated form, lacking the carboxy-terminus, exhibited colony forming eciencies comparable to that of vector transfected clones. The sense derivatives showed signi®cant decrease in colony number and size ( Figure 6B and Table 1 ). In contrast, many of the antisense derivatives showed higher colony forming eciency. These data suggested a growth suppressive activity of mGros1-L.
Chromosomal assignment of Gros1
Genomic PCR with a set of primers from the 3' UTR of human Gros1 cDNA yielded a 120 bp human speci®c product. PCR performed on monochromosomal panels showed its location on chromosome 1 (data not shown) that is syntenous to mouse chromosome 4. PCR on radiation hybrid panels (data not shown) assigned the gene to human chromosome 1p31 (between markers CHLC.GATA65H06 and D1S443). Non-random genetic alterations of chromosome 1p have been shown to be involved in many malignancies as summarized in the introduction suggesting the existence of one or more tumor suppressors at this region. While this study was in progress, WassenhoveMcCarthy and McCarthy, (1999) cloned a rat homolog of Gros1 as a novel basement membrane-associated proteoglycan, leprecan. They have shown that the protein is secreted in the culture medium of rat L-2 cells. Gros-1/leprecan is unrelated to the known proteoglycans core proteins and can be heavily glycosylated by the presence of N-glycosylation and glycosaminoglycan acceptor sites (SG motif) as shown in Figure 7 . Human Gros1-L cDNA sequence predicted the presence of two additional glycosaminoglycan acceptor sites, one at the amino-and other at carboxyterminus ( Figure 7) , may serve for exclusive attachment for chondroitin sulfate (CS) chains implying that Gros1/leprecan may be secreted by cells as a proteoglycan bearing either CS, HS or both chains. The actual number and size of GAG chains attached to Gros1/leprecan remains to be known. The size of the secreted form was identical to that of the cellular form (Wassenhove-McCarthy and McCarthy, 1999) . They have also shown that the secreted form retains C-terminal KDEL signal and present evidence for the secretion of native leprecan. We have found that the short form of the protein hGros1-S that lacks leucine rich repeat can translocate to nucleus in contrast to the long form, hGros1-L which is localized in the cytoplasm. Furthermore, whereas hGros1-L suppressed growth of NIH3T3 cells, its carboxy- , unique to rat Gros1/leprecan, are shown by solid bars Gros1, a potential growth suppressor on chromosome 1 SC Kaul et al terminal truncated mutant (mostly similar to the hGros1-S) had no eect. This alluded that the growth suppressor activity of leprecan can be allocated to its carboxy-terminus and that the two forms of the protein with dierent subcellular localization have dierent functions. Hypervariability of proteoglycans resulting from variation in glycosaminoglycan chain number, length and sulfation is known. This can explain the detection of multiple Gros1 bands by Western blotting in our study, although their exact characterization is a subject of further investigation. Several studies in recent past have shown that proteoglycans, cell surface glycoproteins, interact with extracellular matrix and play an integral role in cell growth, adhesion, migration, tissue development, repair and metastasis by modulating matrix assembly and binding to growth factors (Anttonen et al., 1999; Hocking et al., 1998; Merle et al., 1999) . Expression of heparin sulfate proteoglycan, syndecan-1, is down regulated in carcinomas derived from human epidermis and mammary epithelial cells (Nakanishi et al., 1999) , and inversely related with metastatic potential of human hepatocellular carcinoma cells. Transfection or induction of syndecan-1 by PR-39, a proline-rich antimicrobial peptide, suppresses invasive activity of hepatoma cells suggesting that it may serve as a basis for drug designing or gene therapy eective against metastasis of hepatocellular carcinomas (Fujimoto and Kohgo, 1998) . The addition of intact puri®ed syndecan-1 to myeloma and bone marrow cells in culture has been shown to induce apoptosis, dose-dependent growth inhibition and decrease in osteoblastogenesis (Dhodapkar et al., 1998; Dhodapkar and Sanderson, 1999) . Decorin, a member of the small leucine-rich dermatan/chondroitin sulfate proteoglycan (SLRP) gene family is maximally expressed in quiescent cells, not detectable in transformed ones and down regulated in many tumors. Expression of v-src attenuated decorin expression and transforming growth factor (TGF)-beta activity in MRC-5 cells (Kolettas and Rosenberger, 1998) . Its exogenous expression eectively inhibited the growth of two ovarian cancer lines, SKOV3 and 2774 with an increased expression of p21 WAF1 (Nash et al., 1999) . Rat C6 gliomas also regressed by ectopic expression of decorin. It was mediated by reversal of TGF-beta-induced immunosuppression and activation of the epidermal growth factor (EGF) receptor that triggered a signaling cascade leading to phosphorylation of mitogen-activated protein (MAP) kinase and induction of p21
WAF1
. By virtue of its growth regulatory and immuno-modulatory properties decorin has been proposed as a novel target for the experimental therapy of human cancers (Iozzo et al., 1999; Stander et al., 1998 Stander et al., , 1999 . In addition to their role in histoarchitecture, sequestration of growth factors, cell ± cell and cell ± matrix interactions that recruit them for cancer therapy, proteoglycans have also been implicated to have role in developing mammalian brain (Oohira et al., 2000) , altered elasticity, strength and other physical properties of aging skin (Carrino et al., 2000) and Alzheimer's diseased brain (Verbeek et al., 1999) .
In summary, we have cloned mouse and human proteoglycan, Gros1/leprecan and assigned it to human chromosome 1p31, the region frequently lost in many malignancies. Its two alternative spliced forms encode dierent size proteins that exhibit dierential subcellular localizations. Overexpression of the long form (84-kDa) of the protein is seen to have growth suppressive activity in NIH3T3 cells, consistent with its down regulation in many of the human transformed cells and similar to some other proteoglycans. Based on the structural characterization of the protein (Wassenhove-McCarthy and McCarthy, 1999) , chromosomal localization and biological activity, it may contribute to the tumor suppressor activity lost in many chromosome 1-linked malignancies. Functional mechanism for the role of this novel proteoglycan in growth suppression, signi®cance of dierentially spliced forms and Gros1/leprecan interposed cancer therapy warrants further investigations.
Materials and methods

Cell culture
Normal mouse embryonic ®broblasts from the CD1-ICR strain of mouse (CMEF), an immortal clone (RS-4) established from CMEF, and NIH3T3 cells, initially used for comparison of proteins and cloning studies, were cultured as described (Wadhwa et al., 1991 (Wadhwa et al., , 1993 . Normal human lung (MRC-5), foreskin (HFF5) and bronchial (BF-10) ®broblasts were cultured in Dulbecco's modi®ed Eagle's minimal essential medium supplemented with 10% fetal calf serum. Fibrosarcoma with activated N-ras oncogene (HT1080), cervical carcinoma (HeLa), cytomegalovirustransformed lung ®broblasts (CMV-Mj-HEL-1), lung carcinoma (A549), cervical carcinoma (C33A), glioblastoma (T98G), osteosarcoma (Saos-2) and monkey kidney cells (COS7) were also cultured in DMEM with 10% FCS. Testicular embryonal carcinomas (NEC8 and NEC15) were grown in RPMI1640 supplemented with 10% fetal bovine serum.
cDNA cloning and sequencing
A cDNA library from RS-4 cells was constructed in lZAP II vector and was screened with a polyclonal anti-p33 antibody raised against a protein identi®ed from P-100 fractions of NIH3T3 cells (Wadhwa et al., 1991) . cDNA clones were sequenced by the dideoxy chain termination method and the reactions were analysed on an ABI 377 automated sequencing machine. Full sequence of a 1.0 kb cDNA clone, designated #7, was derived by generation of nested deletions from the 3' end by exonuclease III (Deletion kit, Takara, Tokyo, Japan) and primer walking. Subsequently, this was used to screen mouse and human testis libraries to isolate longer clones.
Preparation of recombinant Gros1 protein and antibody
The 1.0 kb open reading frame (ORF) of #7 cDNA clone was cloned in pQE30 vector (Qiagen) to yield His-tagged protein. The pQE30/#7 constructs were used to transform M15 bacteria, and cells grown to OD 580 =0.6 were induced with isopropyl-1-thio-b-D-galactopyranoside (IPTG) (0.2 mM) at 378C for 5 h. The bacterial lysates (induced and uninduced with IPTG) were analysed by SDS-polyacrylamide gel electrophoresis followed by Western blotting with anti-His (Qiagen) antibody. The recombinant His-tagged protein was used to raise a rabbit polyclonal antibody called anti-Gros1 antibody that was used for Western blotting of mouse, monkey and human cell lysates.
RNA isolation and Northern blot analyses
Total RNA was prepared from cells using Trizol (Life Technologies, Inc). It was denatured and size fractionated on 1% agarose gels containing 2.2 M formaldehyde and transferred to Hybond N + membrane (Amersham Corp.). Mouse and human multiple tissue Northern blots containing 2 mg of poly (A) + RNA per lane were purchased from CLONTECH. A 1.0 kb fragment of the mouse cDNA was used as a probe. Hybridization was performed at 658C in express hybridization buer (CLONTECH). The membrane was washed for 10 min each in 26SSC, 26SSC and 0.1% SDS, then washed in 16SSC and 0.1% SDS twice, and autoradiographed. RNA loading on the blots was determined by hybridization with actin or 18S ribosomal probe.
Western blot
Lysates were prepared from subcon¯uent cultures of control and GFP-Gros1 transfected cells and were separated on an SDS-polyacrylamide gel. The gel was then electroblotted onto a nitrocellulose membrane (BA85, Schleicher and Schuell) using a semidry transfer blotter (Biometra, Tokyo). Anti-GFP (for exogenous protein) and anti-Gros1 antibody (for cellular and secreted forms of the protein) were used for immunodetection.
Subcellular localization
The open reading frames of the long and short forms of human Gros1 were cloned in pEGFPC1 vector (CLON-TECH) to encode GFP-Gros1-L and GFP-Gros1-S proteins. The expression constructs were transfected into COS7 cells growing on coverslips using LipofectAMINE TM (Life Technologies, Inc). After 24 h of transfection, cells were ®xed with 4% formaldehyde in phosphate buered saline (PBS). After three washings in PBS, the coverslips were mounted with Fluoromount (Difco). The cells were examined using a Zeiss Axiophot microscope (Carl Zeiss, Germany) with epi¯uores-cence optics.
Colony forming assay
NIH3T3 cells were stably transfected using LipofectAMI-NE TM (Life Technologies, Inc). Gros1 expression in isolated clones was analysed by Northern blotting as described above. Control, sense and antisense transfectants were analysed for colony forming eciency by plating 500 cells per 10-cm dishes in triplicate. These were left to grow for 2 weeks with the change of medium every 3rd day. Colonies were ®xed with 4% formaldehyde in PBS and were stained with methylene blue. Number of colonies in each dish was counted.
Chromosomal assignment
Polymerase chain reaction (PCR) was performed on genomic DNA (10 ng) from monochromosomal and Genebridge 4 Radiation Hybrid panels (Research Genetics, Inc.) using primers (sense: 5'-TCC CAT CGC ATT ATA ATT AT-3'; antisense, 5'-GCT GCA TAA TAG GCC AAA TTT TGG TT-3') speci®c to human Gros1 (hGros1).
Accession numbers
The nucleotide sequences reported in this paper have been submitted to the GenBankTM/EBI Data Bank with accession number(s) AF097432 (hGros1-L), AF097431 (hGros1-S), AF165163 (mGros1-L), and AF165164 (mGros1-S).
